Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
85
VCYT Quote, Financials, Valuation and Earnings
Last price:
$42.93
Seasonality move
:
-2.04%
Day range:
$41.32 - $43.10
52-week range:
$22.61 - $50.71
Dividend yield:
0%
P/E ratio:
113.07x
P/S ratio:
6.89x
P/B ratio:
2.70x
Volume:
1.2M
Avg. volume:
954K
1-year change:
9.85%
Market cap:
$3.4B
Revenue:
$445.8M
EPS (TTM):
$0.38
Analysts' Opinion
-
Consensus RatingVeracyte, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 2 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $47.50, Veracyte, Inc. has an estimated upside of 10.67% from its current price of $42.92.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $43.00 representing 100% downside risk from its current price of $42.92.
Fair Value
-
According to the consensus of 11 analysts, Veracyte, Inc. has 10.67% upside to fair value with a price target of $47.50 per share.
VCYT vs. S&P 500
-
Over the past 5 trading days, Veracyte, Inc. has overperformed the S&P 500 by 0.08% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Veracyte, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Veracyte, Inc. has grown year-over-year revenues for 21 quarters straight. In the most recent quarter Veracyte, Inc. reported revenues of $131.9M.
Earnings Growth
-
Veracyte, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Veracyte, Inc. reported earnings per share of $0.24.
Enterprise value:
3.1B
EV / Invested capital:
2.36x
Price / LTM sales:
6.89x
EV / EBIT:
62.05x
EV / Revenue:
6.19x
PEG ratio (5yr expected):
-0.48x
EV / Free cash flow:
31.23x
Price / Operating cash flow:
34.75x
Enterprise value / EBITDA:
42.72x
Gross Profit (TTM):
$331M
Return On Assets:
2.28%
Net Income Margin (TTM):
6.12%
Return On Equity:
2.52%
Return On Invested Capital:
2.43%
Operating Margin:
17.53%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $343.1M | $425.3M | $495.1M | $115.9M | $131.9M | |
| Gross Profit | $207.5M | $276.2M | $331M | $76.7M | $89.4M | |
| Operating Income | -$13M | $11.3M | $49.4M | $12.2M | $23.1M | |
| EBITDA | $17.2M | $34.8M | $71.8M | $18.1M | $28.4M | |
| Diluted EPS | -$0.69 | -$0.14 | $0.38 | $0.19 | $0.24 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $229.3M | $238.5M | $271.2M | $356.9M | $449.2M | |
| Total Assets | $1.2B | $1.1B | $1.1B | $1.3B | $1.4B | |
| Current Liabilities | $50M | $58.4M | $57.3M | $70.3M | $72.2M | |
| Total Liabilities | $79.3M | $77.8M | $70.9M | $99M | $110.1M | |
| Total Equity | $1.1B | $1B | $1.1B | $1.2B | $1.3B | |
| Total Debt | $15.3M | $12.7M | $8.7M | $12.4M | $36.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $38.4M | $66.1M | $108.2M | $30M | $44.8M | |
| Cash From Investing | -$8.8M | -$4.6M | -$57.9M | -$2.2M | $48.3M | |
| Cash From Financing | $2.3M | $10.1M | -$8.6M | $10.3M | $3M | |
| Free Cash Flow | $29.1M | $56.5M | $98.2M | $27.7M | $42M | |
VCYT
Sector
Market Cap
$3.4B
$27.9M
Price % of 52-Week High
84.64%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-0.66%
-1.49%
1-Year Price Total Return
9.85%
-16.66%
Beta (5-Year)
1.829
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$42.79
200-day SMA
Buy
Level
$32.23
Bollinger Bands (100)
Buy
Level
29.64 - 42.02
Chaikin Money Flow
Buy
Level
348
20-day SMA
Sell
Level
$44.90
Relative Strength Index (RSI14)
Buy
Level
50.16
ADX Line
Sell
Level
19.93
Williams %R
Neutral
Level
-76.4012
50-day SMA
Buy
Level
$40.66
MACD (12, 26)
Buy
Level
7.98
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Sell
Level
-219.9K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.9059)
Buy
CA Score
(Annual)
Level (1.6252)
Buy
Beneish M-Score
(Annual)
Level (-2.613)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-4.7969)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, VCYT has received 8 Buy ratings 2 Hold ratings, and 1 Sell ratings. The VCYT average analyst price target in the past 3 months is $47.50.
-
Where Will Veracyte, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Veracyte, Inc. share price will rise to $47.50 per share over the next 12 months.
-
What Do Analysts Say About Veracyte, Inc.?
Analysts are divided on their view about Veracyte, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Veracyte, Inc. is a Sell and believe this share price will drop from its current level to $43.00.
-
What Is Veracyte, Inc.'s Price Target?
The price target for Veracyte, Inc. over the next 1-year time period is forecast to be $47.50 according to 11 Wall Street analysts, 8 of them rate the stock a Buy, 1 rates the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is VCYT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Veracyte, Inc. is a Buy. 8 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VCYT?
You can purchase shares of Veracyte, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Veracyte, Inc. shares.
-
What Is The Veracyte, Inc. Share Price Today?
Veracyte, Inc. was last trading at $42.93 per share. This represents the most recent stock quote for Veracyte, Inc.. Yesterday, Veracyte, Inc. closed at $42.92 per share.
-
How To Buy Veracyte, Inc. Stock Online?
In order to purchase Veracyte, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get VCYT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
VCYT
Sector
P/E ratio
113.07x
23.85x
PEG ratio
-0.48x
-0.01x
P/B ratio
2.70x
1.81x
Price / LTM sales
6.89x
1.58x
Growth Metrics
VCYT
Sector
Revenue growth
13.82%
4.62%
Earnings growth
24.34%
10.5%
Revenue (5-year growth)
29.93%
6.5%
Earnings forecast
$0.32
-$0.21
Profitability
VCYT
Sector
Profitability FY 2024
$289.5M
$3.6M
Return on invested capital
2.43%
-31.87%
Return on assets
2.28%
-28.18%
Return on equity
2.52%
-37.63%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Feb
3
Balance Sheet
VCYT
Sector
Total cash
$366.4M
$26.4M
Short term investments
$50.4M
$25.7M
Total assets
$1.3B
$76.9M
Long term debt
$36.2M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
